]>
IRCT20190814044528N1 IRCT 2020-02-02 Ahvaz University of Medical Sciences The effect of using different contrast agents in CT scan on radiation dose during radiotherapy Comparison of Radiation Dose Calculated by treatment planning System (TPS) of Radiation Therapy in CT Imaging of three Prostate Cancer Patients groups that have been Imaging with Three Different contrast agents Omnipaque, Visipaque and Ultravist 2020-04-03 anticipated 30 Complete https://irct.ir/trial/41504 interventional Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Basic scienece, Randomization description: A computer-generated randomization list will be developed for patients by the statistical consultant and another off-site person with no knowledge of goals of study(CT expert) according to this list,will give patients three different contrast agents: Omnipaque, Visipaque and Ultravist. 4 Prostate Cancer. Intervention 1: First Intervention group: prostate cancer Patients whose CT imaging done with intravenous injection of Visipaque contrast agent and it will be given a standard injection of 1 ml per kg of body weight. Imaging will take one to two minutes after intravenous injection. Intervention 2: Second Intervention group:prostate cancer Patients whose CT imaging done with intravenous injection of Omnipaque contrast agent and it will be given a standard injection of 1 ml per kg of body weight. Imaging will take one to two minutes after intravenous injection. Intervention 3: Third Intervention group: prostate cancer Patients whose CT imaging done with intravenous injection of Ultravist contrast agent and it will be given a standard injection of 1 ml per kg of body weight. Imaging will take one to two minutes after intravenous injection. No - There is not a plan to make this available Justification or reason for not sharing IPD is There is no need to publish raw patient data and the results of the study should be published comparatively.
public Marzieh Reshadatian
Esfand street, Golestan region
Ahvaz Iran (Islamic Republic of) 1579461357 +98 61 3333 3477 m.reshadatian@gmail.com Ahvaz University of Medical Sciences scientific Mohsen Cheky
Esfand street, Golestan region
Ahvaz Iran (Islamic Republic of) 1579461357 +98 61 3336 7540 mohsencheky@gmail.com Ahvaz University of Medical Sciences Iran (Islamic Republic of) Prostate cancer patients who are referred to the CT scan ward for CT imaging and don't have the exclusion criteria no limit no limit Male Patients under 18 years old Patients with kidney problems Diabetic patients Patients with a history of asthma and immunological allergies People who had allergy to the use of contrast agents in the past C61 Malignant neoplasm of prostate Diagnosis Diagnosis Diagnosis First Intervention group: prostate cancer Patients whose CT imaging done with intravenous injection of Visipaque contrast agent and it will be given a standard injection of 1 ml per kg of body weight. Imaging will take one to two minutes after intravenous injection. Second Intervention group:prostate cancer Patients whose CT imaging done with intravenous injection of Omnipaque contrast agent and it will be given a standard injection of 1 ml per kg of body weight. Imaging will take one to two minutes after intravenous injection. Third Intervention group: prostate cancer Patients whose CT imaging done with intravenous injection of Ultravist contrast agent and it will be given a standard injection of 1 ml per kg of body weight. Imaging will take one to two minutes after intravenous injection. Radiation dose of the patient. Timepoint: After CT imaging with injection of contrast material. Method of measurement: Radiotherapy treatment planning software (TPS). Ahvaz University of Medical Sciences Approved 2019-11-23 Ethics committee of Ahvaz Jundishapur University of Medical Sciences Esfand avenue, Golestan street Ahvaz Khouzestan Iran (Islamic Republic of)